netFormulary
 Report : Medicines with links to NICE 20/08/2019 13:58:03

[Back]

Report looks at the links table and pulls back all the items in the formulary where there is a link with 'nice.org' in the URL

You can sort this table Medicines Link Name or Link URL by clicking on the title

Selecting the Medicine name will take you to the entry in the formulary, Selecting the Link name will follow the link

 
Medicines/Item Section Status Link Name / Link URL
Abatacept 10.01.03 Restricted Use NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis (December 2015)
Abatacept 10.01.03 Restricted Use NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed (January 2016)
Abatacept 10.01.03 Restricted Use NICE TA195: Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor [August 2010]
Abatacept 10.01.03 Restricted Use NICE TA280: Abatacept for treating rheumatoid arthritis after the failure of conventional disease-modifying anti-rheumatic drugs [April 2013]
Abemaciclib tablets 08.01.05 Restricted Use NICE TA563: Abemaciclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer (February 2019)
Abemaciclib tablets 08.01.05 Restricted Use NICE TA579: Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy (May 2019)
Abiraterone Acetate 08.03.04.02 Restricted Use NICE TA387: Abiraterone for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated (July 2016)
Abiraterone Acetate 08.03.04.02 Restricted Use NICE TA259: Abiraterone for castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen (July 2016)
Adalimumab 10.01.03 Restricted Use NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed (January 2016)
Adalimumab 10.01.03 Restricted Use NICE TA199: Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis [August 2010]
Adalimumab 10.01.03 Restricted Use NICE TA455: Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people (July 2017)
Adalimumab 10.01.03 Restricted Use NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis (February 2016)
Adalimumab 10.01.03 Restricted Use NICE TA329: Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (February 2015)
Adalimumab 10.01.03 Restricted Use NICE TA392: Adalimumab for treating moderate to severe hidradenitis suppurativa
Adalimumab 10.01.03 Restricted Use NICE TA143: Adalimumab, etanercept and infliximab for ankylosing spondylitis [May 2008]
Adalimumab 10.01.03 Restricted Use NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis (December 2015)
Adalimumab Subcutaneous Injection 01.05.03 Restricted Use NICE TA187: Infliximab and adalimumab for the treatment of Crohn’s disease (May 2010)
Adalimumab Subcutaneous Injection 01.05.03 Restricted Use NICE TA460: Adalimumab and dexamethasone for treating non-infectious uveitis (July 2017)
Adalimumab Subcutaneous Injection 01.05.03 Restricted Use NICE TA 329: Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (February 2015)
Adefovir Dipivoxil 05.03.03 Non Formulary NICE TA96: Hepatitis B (chronic) - adefovir dipivoxil and pegylated interferon alpha-2a
Afatinib 08.01.05 Restricted Use NICE TA310: Afatinib for treating epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer (April 2014)
Aflibercept 11.08.02 Restricted Use NICE TA294: Aflibercept solution for injection for treating wet age‑related macular degeneration (July 2013)
Aflibercept 11.08.02 Restricted Use NICE TA305: Aflibercept for treating visual impairment caused by macular oedema secondary to central retinal vein occlusion (February 2014)
Aflibercept 11.08.02 Restricted Use TA346: Aflibercept for treating diabetic macular oedema (July 2015)
Aflibercept 11.08.02 Restricted Use NICE TA307: Aflibercept in combination with irinotecan and fluorouracil-based therapy for treating metastatic colorectal cancer that has progressed following prior oxaliplatin-based chemotherapy (March 2014)
Aflibercept 11.08.02 Restricted Use NICE TA409: Aflibercept for treating visual impairment caused by macular oedema after branch retinal vein occlusion (September 2016)
Aflibercept 11.08.02 Restricted Use NICE TA486: Aflibercept for treating choroidal neovascularisation (November 2017)
Alectinib capsules 08.01.05 Restricted Use NICE TA536: Alectinib for untreated ALK-positive advanced non-small-cell lung cancer (August 2018)
Alendronic Acid 06.06.02 Formulary NICE TA161: Alendronate, etidronate, risedronate, raloxifene, strontium ranelate and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women (February 2018)
Alendronic Acid 06.06.02 Formulary NICE TA464: Bisphosphonates for treating osteoporosis (February 2018))
Alendronic Acid 06.06.02 Formulary NICE TA160: Alendronate, etidronate, risedronate, raloxifene and strontium ranelate for the primary prevention of osteoporotic fragility fractures in postmenopausal women (February 2018)
Alirocumab 02.12 Formulary NICE TA393: Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia (June 2016)
Alitretinoin 13.05.01 Non Formulary NICE TA177: Eczema (chronic) - alitretinoin
Alogliptin 06.01.02.03 Formulary NICE NG28:Type 2 diabetes in adults: management (May 2017)
Alteplase 02.10.02 Restricted Use NICE TA264: Alteplase for treating acute ischaemic stroke (September 2012)
Aluminimum Hydroxide 01.01.01 Non Formulary Obinutuzumab in combination with chlorambucil for untreated chronic lymphocytic leukaemia
Aluminimum Hydroxide 01.01.01 Non Formulary Olaparib for maintenance treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy (January 2016)
Aluminimum Hydroxide 01.01.01 Non Formulary Olaparib for maintenance treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy
Aluminimum Hydroxide 01.01.01 Non Formulary Olaparib for maintenance treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy
Amitriptyline 04.07.03 Formulary NICE CG173: Neuropathic pain in adults: pharmacological management in non-specialist settings (April 2018)
Anastrozole 08.03.04.01 Formulary NICE CG164: Familial Breast Cancer (updated March 2017)
Anti-D (Rh0) Immunoglobulin 14.05.03 Non Formulary NICE TAG156: Anti-D in pregnant women
Apixaban 02.08.02 Formulary NICE TA275: Apixaban for preventing stroke and systemic embolism in people with non-valvular atriall fibrillation (February 2013)
Apixaban 02.08.02 Formulary NICE TA341: Apixaban for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism (June 2015)
Apixaban 02.08.02 Formulary NICETA 245: Apixaban for the prevention of venous thromboembolism after total hip or knee replacement in adults (January 2012)
Apremilast 10.01.03 Formulary NICE TA372: Apremilast for treating Psoriatic arthritis (December 2015)
Apremilast 10.01.03 Formulary NICE TA419: Apremilast for treating moderate to severe plaque psoriasis (Nov 2016)
Apremilast 10.01.03 Formulary NICE TA368: Apremilast for treating moderate to severe plaque psoriasis (November 2015)
Apremilast 10.01.03 Formulary NICE TA433: Apremilast for treating active psoriatic arthritis (Feb 2017)
Atezolizumab infusion 08.01.05 Restricted Use NICE TA584: Atezolizumab in combination for treating metastatic non-squamous non-small-cell lung cancer (June 2019)
Atezolizumab infusion 08.01.05 Restricted Use NICE TA525: Atezolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy (June 2018)
Atezolizumab infusion 08.01.05 Restricted Use NICE TA520: Atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer after chemotherapy (May 2018)
Atezolizumab infusion 08.01.05 Restricted Use NICE TA492: Atezolizumab for untreated locally advanced or metastatic urothelial cancer when cisplatin is unsuitable (December 2017)
Axitinib 08.01.05 Restricted Use NICE TA333: Axitinib for treating advanced renal cell carcinoma after failure of prior systemic treatment (Februaury 2015)
Azacitidine 08.01.03 Restricted Use NICE TA218: Azacitidine for the treatment of myelodysplastic syndromes, chronic myelomonocytic leukaemia and acute myeloid leukaemia (March 2011)
Baricitinib 10.01.03 Restricted Use NICE TA466: Baricitinib for moderate to severe rheumatoid arthritis
Bendamustine 08.01.01 Restricted Use NICE TA216: Bendamustine for the first-line treatment of chronic lymphocytic leukaemia (February 2011)
Bendamustine 08.01.01 Restricted Use NICE TA472: Obinutuzumab with bendamustine for treating follicular lymphoma refractory to rituximab (August 2017)
Benralizumab 03.04.02 Restricted Use NICE TA565: Benralizumab for treating severe eosinophilic asthma (March 2019)
Bevacizumab 08.01.05 Restricted Use NICE TA263: Bevacizumab in combination with capecitabine for the first-line treatment of metastatic breast cancer (August 2012) [Do not recommend]
Bevacizumab 08.01.05 Restricted Use NICE TA214: Bevacizumab in combination with a taxane for the first-line treatment of metastatic breast cancer (February 2011) [Do not recommend]
Bivalirudin 02.08.01 Non Formulary NICE TA230: Bivalirudin for the treatment of STEMI, 2011
Boceprevir 05.03.03.02 Restricted Use NICE TA253: Boceprevir for the treatment of genotype 1 chronic hepatitis C (April 2012)
Bortezomib 08.01.05 Restricted Use NICE TA228: Bortezomib and thalidomide for the first-line treatment of multiple myeloma (July 2011)
Bortezomib 08.01.05 Restricted Use NICE TA370: Bortezomib for previously untreated mantle cell lymphoma (December 2015)
Bortezomib 08.01.05 Restricted Use NICE TA129: Bortezomib monotherapy for relapsed multiple myeloma (October 2007)
Bosutinib 08.01.05 Restricted Use NICE TA401: Bosutinib for previously treated chronic myeloid leukaemia (August 2016)
Botulinum Toxin Type A 04.09.03 Restricted Use NICE TA260: Botox for migraine prophylaxis June 2012)
Brentuximab infusion 08.01.05 Restricted Use NICE TA577: Brentuximab vedotin for treating CD30-positive cutaneous T-cell lymphoma (April 2019)
Brentuximab infusion 08.01.05 Restricted Use NICE TA478: Brentuximab vedotin for treating relapsed or refractory systemic anaplastic large cell lymphoma (October 2017)
Brentuximab infusion 08.01.05 Restricted Use NICE TA446: Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma (June 2017)
Brentuximab infusion 08.01.05 Restricted Use NICE TA524: Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma (June 2018)
Brigatinib tablets 08.01.05 Restricted Use NICE TA571:Brigatinib for treating ALK-positive advanced non-small-cell lung cancer after crizotinib (March 2019)
Brodalumab 10.01.03 Restricted Use NICE TA511: Brodalumab for treating moderate to severe plaque psoriasis (March 2018)
Cabazitaxel 08.01.05 Restricted Use NICE TA391: Cabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxel (May 2016)
Canagliflozin 06.01.02.03 Formulary NICE TA315: Canagliflozin in combination therapy for treating type 2 diabetes (June 2014)
Canagliflozin 06.01.02.03 Formulary NICE TA390: Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes. (May 2016)
Capecitabine 08.01.03 Restricted Use NICE TA100: Capecitabine and oxaliplatin in the adjuvant treatment of stage III (Dukes’ C) colon cancer (April 2006)
Capecitabine 08.01.03 Restricted Use NICE TA191: Capecitabine for the treatment of advanced gastric cancer (July 2010)
Carfilzomib 08.01.05 Restricted Use NICE TA457: Carfilzomib for previously treated multiple myeloma (July 2017)
Carmustine 08.01.01 Non Formulary NICE TA121: Glioma (newly diagnosed and high grade) - carmustine implants and temozolomide
Carmustine 08.01.01 Non Formulary NICE TA121: Glioma (newly diagnosed and high grade) - carmustine implants and temozolomide
Ceritinib capsules 08.01.05 Restricted Use NICE TA395: Ceritinib for previously treated anaplastic lymphoma kinase positive non-small-cell lung cancer (June 2016)
Ceritinib capsules 08.01.05 Restricted Use NICE TA500: Ceritinib for untreated ALK-positive non-small-cell lung cancer (January 2018)
Certolizumab Pegol 10.01.03 Restricted Use NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis (February 2016)
Certolizumab Pegol 10.01.03 Restricted Use NICE TA186: Certolizumab pegol for the treatment of rheumatoid arthritis [February 2010]
Certolizumab Pegol 10.01.03 Restricted Use NICE TA574: Certolizumab pegol for treating moderate to severe plaque psoriasis (April 2019)
Certolizumab Pegol 10.01.03 Restricted Use NICE TA415: Certolizumab pegol for treating rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor
Certolizumab Pegol 10.01.03 Restricted Use NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed (Januray 2016)
Certolizumab Pegol 10.01.03 Restricted Use NICE TA445: Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs (May 2017)
Cetuximab 08.01.05 Restricted Use NICE TA176: Cetuximab for the first-line treatment of metastatic colorectal cancer (August 2009)
Cetuximab 08.01.05 Restricted Use TA439: Cetuximab and panitumumab for previously untreated metastatic colorectal cancer (March 2017)
Cetuximab 08.01.05 Restricted Use NICE TA172: Cetuximab for the treatment of recurrent and/or metastatic squamous cell cancer of the head and neck (June 2009) NOT RECOMMENDED
Cetuximab 08.01.05 Restricted Use NICE TA145: Cetuximab for the treatment of locally advanced squamous cell cancer of the head and neck (June 2008) [Specialist Centre Only)
Cetuximab 08.01.05 Restricted Use NICE TA118: Bevacizumab and Cetuximab for the Treatment of Metastatic Colorectal Cancer (Updated January 2012). NOT RECOMMENDED
Cetuximab 08.01.05 Restricted Use NICE TA473: Cetuximab for treating recurrent or metastatic squamous cell cancer of the head and neck (August 2017)
Ciclosporin 0.1% 11.99.99.99 Formulary NICE TA369: Ciclosporin for treating dry eye disease that has not improved despite treatment with artificial tears (Dec 2015)
Cinacalcet 09.05.01.02 Restricted Use NICE TA117 Cinacalcet for the treatment of secondary hyperparathyroidism in patients with end-stage renal disease on maintenance dialysis therapy [January 2007]
Collagenase clostridium histolyticum injection 10.03.01 Restricted Use NICE TA459: Collagenase clostridium histolyticum for treating Dupuytren’s contracture
Crizotinib 08.01.05 Restricted Use NICE TA529: Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer (July 2018)
Crizotinib 08.01.05 Restricted Use NICE TA422: Crizotinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer (December 2016)
Crizotinib 08.01.05 Restricted Use NICE TA406: Crizotinib for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer (September 2016)
Dabigatran etexilate 02.08.02 Formulary NICE TA249: Dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation (March 2012)
Daclatasvir 05.03.03.02 Restricted Use NICE TA364: Daclatasvir for treating chronic hepatitis C (November 2015)
Dapagliflozin 06.01.02.03 Restricted Use NICE TA288: Type 2 diabetes - Dapagliflozin combination therapy (June 2013)
Dapagliflozin 06.01.02.03 Restricted Use NICE TA418: Dapagliflozin in triple therapy for treating type 2 diabetes (Nov 2016)
Dapagliflozin 06.01.02.03 Restricted Use NICE TA390: Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes (May 2016)
Daratumumab infusion 08.01.05 Restricted Use NICE TA510: Daratumumab monotherapy for treating relapsed and refractory multiple myeloma (March 2018)
Daratumumab infusion 08.01.05 Restricted Use NICE TA573: Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma (April 2019)
Darbepoetin alfa 09.01.03 Restricted Use NICE TA323: Erythropoiesis‑stimulating agents (epoetin and darbepoetin) for treating anaemia in people with cancer having chemotherapy [November 2014]
Dasabuvir 05.03.03.02 Restricted Use NICE TA365: Ombitasvir-paritaprevir-ritonavir with or without dasabuvir for treating chronic hepatitis C (Nov 2015)
Dasatinib 08.01.05 Non Formulary NICE TA241:CML for whom treatment with imatinib has failed because of intolerance
Dasatinib 08.01.05 Restricted Use NICE TA425: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia (December 2016)
Dasatinib 08.01.05 Restricted Use NICE TA426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia (December 2016)
Degarelix Injection 08.03.04.02 Restricted Use NICE TA404: Degarelix for treating advanced hormone-dependent prostate cancer (August 2016)
Denosumab 06.06.02 Restricted Use NICE TA204: Denosumab for the prevention of osteoporotic fractures in postmenopausal women (2010)
Dexamethasone 11.04.01 Restricted Use NICE TA229: Dexamethasone intravitreal implant for the treatment of macular oedema (July 2011)
Dexamethasone 11.04.01 Restricted Use NICE TA460:Adalimumab and dexamethasone for treating non-infectious uveitis (July 2017)
Dexamethasone 11.04.01 Restricted Use NICE TA349: Dexamethasone intravitreal implant for treating diabetic macular oedema (July 2015)
Dexamethasone 04.06 Restricted Use NICE TA505: Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma (February 2018)
Dimethyl fumarate 08.02.04 Restricted Use NICE TA320: Dimethyl fumarate for treating relapsing‑remitting multiple sclerosis (August 2014)
Dimethyl fumarate 08.02.04 Restricted Use NICE TA475: Dimethyl fumarate for treating moderate to severe plaque psoriasis (September 2017)
Dipyridamole 02.09 Restricted Use NICE TA210: Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events (December 2010)
Dipyridamole and Aspirin 02.09 Restricted Use NICE TA210: Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events (December 2010)
Docetaxel 08.01.05 Restricted Use NICE TA509: Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer (March 2018)
Docetaxel 08.01.05 Restricted Use NICE TA101: Docetaxel for the treatment of hormone-refractory metastatic prostate cancer (June 2006)
Docetaxel 08.01.05 Restricted Use NICE TA109: Docetaxel for the adjuvant treatment of early node-positive breast cancer (September 2006)
Donepezil 04.11 Restricted Use NICE TA217: Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer’s disease (June 2018)
Doxorubicin Hydrochloride 08.01.02 Restricted Use NICE TA389: Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer (April 2016)
Dronedarone 02.03.02 Restricted Use NICE TA197: Dronedarone for the treatment of non-permanent atrial fibrillation (updated Dec 2012)
Dupilumab 13.05.03 Restricted Use NICE TA534: Dupilumab for treating moderate to severe atopic dermatitis (August 2018)
Durvalumab 08.01.05 Restricted Use NICE TA578: Durvalumab for treating locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation (May 2019)
Eculizumab Injection 09.01.03 Restricted Use NICE HST1: Eculizumab for treating atypical haemolytic uraemic syndrome [January 2015]
Edoxaban 02.08.02 Formulary NICE TA355 - Edoxaban for preventing stroke and systemic embolism in people with non‑valvular atrial fibrillation (Sept 2015)
Edoxaban 02.08.02 Formulary NICE TA354 - Edoxaban for treating and for preventing deep vein thrombosis and pulmonary embolism (Aug 2015)
Elbasvir-grazoprevir 05.03.03.02 Restricted Use NICE TA413: Elbasvir–grazoprevir for treating chronic hepatitis C (Oct 2016)
Eltrombopag 09.01.04 Restricted Use NICE TA293: Eltrombopag for treating chronic immune (idiopathic) thrombocytopenic purpura (July 2013)
Eltrombopag 09.01.04 Non Formulary NICE guidance 2010
Eluxadoline 01.04.02 Formulary TA471: Eluxadoline for treating irritable bowel syndrome with diarrhoea
Empagliflozin 06.01.02.03 Formulary NICE TA336: Empagliflozin in combination therapy for treating type 2 diabetes (March 2015)
Empagliflozin 06.01.02.03 Formulary NICE TA390: Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes (May 2016)
Entecavir 05.03.03.01 Restricted Use NICE TA153: Entecavir for the treatment of chronic hepatitis B (Aug 2008)
Entecavir 05.03.03 Non Formulary NICE TA153: Hepatitis B - entecavir
Enzalutamide 08.03.04.02 Restricted Use NICE TA377: Enzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated (January 2016)
Enzalutamide 08.03.04.02 Restricted Use NICE TA316: Enzalutamide for metastatic hormone-relapsed prostate cancer, previously treated with docetaxel-containing regimen (July 2014)
Eplerenone 02.02.03 Restricted Use NICE CG108: Chronic heart failure in adults: management (Aug 2010)
Epoetin alfa 09.01.03 Restricted Use NICE TA323: Erythropoiesis‑stimulating agents (epoetin and darbepoetin) for treating anaemia in people with cancer having chemotherapy [November 2014]
Epoetin beta 09.01.03 Restricted Use NICE TA323: Erythropoiesis‑stimulating agents (epoetin and darbepoetin) for treating anaemia in people with cancer having chemotherapy [November 2014]
Epoetin zeta 09.01.03 Restricted Use NICE TA 323: Erythropoiesis‑stimulating agents (epoetin and darbepoetin) for treating anaemia in people with cancer having chemotherapy (November 2014)
Eribulin 08.01.05 Restricted Use NICE TA423: Eribulin for treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens (December 2016)
Eribulin 08.01.05 Restricted Use NICE TA515: Eribulin for treating locally advanced or metastatic breast cancer after 1 chemotherapy regimen (March 2018)
Erlotinib 08.01.05 Restricted Use NICE TA258: Erlotinib for the first-line treatment of locally advanced or metastatic EGFR-TK mutation-positive non-small-cell lung cancer (June 2012)
Erlotinib 08.01.05 Restricted Use NICE TA374: Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy (December 2015)
Erlotinib 08.01.05 Restricted Use NICE TA227: Erlotinib monotherapy for maintenance treatment of non-small-cell lung cancer [Not recommended] (June 2011)
Ertugliflozin 06.01.02.03 Formulary NICE TA572: Ertugliflozin as monotherapy or with metformin for treating type 2 diabetes (March 2019)
Etanercept 13.05.03 Non Formulary NICE TA103: Psoriasis - efalizumab and etanercept
Etanercept 10.01.03 Restricted Use NICE TA199: Psoriatic arthritis - etanercept, infliximab and adalimumab [August 2010]
Etanercept 10.01.03 Restricted Use NICE TA195: Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor [August 2010]
Etanercept 10.01.03 Restricted Use NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed (January 2016)
Etanercept 10.01.03 Restricted Use NICE TA455: Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people (July 2017)
Etanercept 10.01.03 Restricted Use NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis (December 2015)
Etanercept 10.01.03 Restricted Use NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis (February 2016)
Etelcalcetide 06.06.01 Formulary NICE TA448: Etelcalcetide for treating secondary hyperparathyroidism (June 2017)
Everolimus 08.01.05 Restricted Use NICE TA432: Everolimus for advanced renal cell carcinoma after previous treatment (Feb 2017) [Specialist Centre Only]
Everolimus 08.01.05 Restricted Use NICE TA421: Everolimus with exemestane for treating advanced breast cancer after endocrine therapy (December 2016)
Everolimus 08.01.05 Restricted Use NICE TA348: Everolimus for preventing organ rejection in liver transplantation (July 2015)
Everolimus 08.01.05 Restricted Use NICE TA 449: Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease (June 2017) [Specialist Centre Only]
Everolimus 08.01.05 Restricted Use NICE TA219: Everolimus for the second-line treatment of advanced renal cell carcinoma (April 2011) NOT RECOMMENDED [Specialist Centre Only]
Everolimus 08.01.05 Restricted Use NICE TA498: Lenvatinib with everolimus for previously treated advanced renal cell carcinoma (January 2018) [Specialist Centre Only]
Evolocumab 02.12 Formulary NICE TA394: Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia (June 2016)
Exemestane 08.03.04.01 Formulary NICE TA421: Everolimus with exemestane for treating advanced breast cancer after endocrine therapy (December 2016)
Exenatide 06.01.02.03 Restricted Use NG28:Type 2 diabetes in adults: management (May 2017)
Ezetimibe 02.12 Restricted Use NICE TA385: Ezetimibe for treating primary heterozygous-familial and non-familial hypercholesterolaemia (Febuary 2016)
Febuxostat 10.01.04 Restricted Use NICE TA164: Febuxostat for the management of hyperuricaemia in people with gout [December 2008]
Fingolimod 08.02.04 Non Formulary NICE TA254: Fingolimod for highly active relapsing remitting multiple sclerosis
Fludarabine Phosphate 08.01.03 Restricted Use NICE TA119: Fludarabine monotherapy for the first-line treatment of chronic lymphocytic leukaemia (February 2007)
Fludarabine Phosphate 08.01.03 Restricted Use NICE TA29: Guidance on the use of fludarabine for B-cell chronic lymphocytic leukaemia (September 2001)
Fluticasone and salmeterol 03.02 Formulary NICE TA138: Inhaled Corticosteroids for the Treatment of Chronic Asthma in Adults and Children over 12 years (March 2008)
Fondaparinux Sodium 02.08.01 Formulary NICE CG94: Unstable angina and NSTEMI: early management (Updated Nov 13)
Fulvestrant 08.03.04.01 Restricted Use NICE TA503: Fulvestrant for untreated locally advanced or metastatic oestrogen-receptor positive breast cancer (January 2018)
Fulvestrant 08.03.04.01 Restricted Use NICE TA239: Fulvestrant for the treatment of locally advanced or metastatic breast cancer (December 2011)
Galantamine 04.11 Restricted Use NICE TA217: Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer’s disease (June 2018)
Gefitinib 08.01.05 Restricted Use NICE TA192: Gefitinib for the first-line treatment of locally advanced or metastatic non-small-cell lung cancer (July 2010)
Gefitinib 08.01.05 Restricted Use NICE TA374: Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy (December 2015)
Gemcitabine 08.01.03 Restricted Use NICE TA25: Guidance on the use of gemcitabine for the treatment of pancreatic cancer (May 2001)
Gemcitabine 08.01.03 Restricted Use NICE TA476: Paclitaxel as albumin-bound nanoparticles with gemcitabine for untreated metastatic pancreatic cancer (September 2017)
Gemcitabine 08.01.03 Restricted Use NICE TA116: Gemcitabine for the treatment of metastatic breast cancer (January 2007)
Glecaprevir/pibrentasvir tablets 05.03.03.02 Restricted Use NICE TA499: Glecaprevir–pibrentasvir for treating chronic hepatitis C (January 2018)
GLIADEL wafer Carmustine 7.6mg 20 Non Formulary NICE TA121: Glioma (newly diagnosed and high grade) - carmustine implants and temozolomide
Golimumab 10.01.03 Restricted Use NICE TA233: Golimumab for the treatment of ankylosing spondylitis [August 2011]
Golimumab 10.01.03 Restricted Use NICE TA220: Golimumab for the treatment of psoriatic arthritis [April 2011]
Golimumab 10.01.03 Restricted Use NICE TA225: Golimumab for the treatment of rheumatoid arthritis after the failure of previous disease-modifying anti-rheumatic drugs [June 2011]
Golimumab 10.01.03 Restricted Use NICE TA497: Golimumab for treating non-radiographic axial spondyloarthritis (January 2018)
Golimumab 10.01.03 Restricted Use NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed (January 2016)
Golimumab 10.01.03 Restricted Use NICE TA329: Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (February 2015)
Golimumab 10.01.03 Restricted Use NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis (February 2016)
Golimumab Subcutaneous Injection 01.05.03 Restricted Use NICE TA 329: Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (February 2015)
Guselkumab 10.01.03 Restricted Use NICE TA521: Guselkumab for treating moderate to severe plaque psoriasis (June 2018)
Human anti-D immunoglobulin 14.05.03 Formulary NICE TA156: Routine antenatal anti-D prophylaxis for women who are rhesus D negative (August 2008)
Ibandronic Acid 06.06.02 Restricted Use NICE TA464: Bisphosphonates for treating osteoporosis (February 2018)
Ibrutinib 08.01.05 Restricted Use NICE TA429: Ibrutinib for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation (January 2017)
Ibrutinib 08.01.05 Restricted Use NICE TA491: Ibrutinib for treating Waldenstrom’s macroglobulinaemia (November 2017)
Ibrutinib 08.01.05 Restricted Use NICE TA502: Ibrutinib for treating relapsed or refractory mantle cell lymphoma (January 2018)
Ibrutinib 08.01.05 Restricted Use NICE TA502: Ibrutinib for treating relapsed or refractory mantle cell lymphoma (January 2018)
Ibrutinib 08.01.05 Restricted Use Ibrutinib for treating Waldenstrom’s macroglobulinaemia (November 2017)
Idelalisib 08.01.05 Restricted Use NICE TA359 Idelalisib for treating chronic lymphocytic leukaemia (October 2015)
Imatinib 08.01.05 Restricted Use NICE TA426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia (December 2016)
Imatinib 08.01.05 Restricted Use NICE TA86: Imatinib for the treatment of unresectable and/or metastatic gastro-intestinal stromal tumours (November 2010)
Imatinib 08.01.05 Restricted Use NICE TA70: Guidance on the use of imatinib for chronic myeloid leukaemia (January 2016)
Imatinib 08.01.05 Restricted Use NICE TA209: Imatinib for the treatment of unresectable and/or metastatic gastrointestinal stromal tumours (November 2010)
Imatinib 08.01.05 Restricted Use NICE TA425: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia (December 2016)
Infliximab 10.01.03 Restricted Use NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis (February 2016)
Infliximab 10.01.03 Restricted Use NICE TA143: Adalimumab, etanercept and infliximab for ankylosing spondylitis [May 2008]
Infliximab 10.01.03 Restricted Use NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed (January 2016)
Infliximab 10.01.03 Restricted Use NICE TA329: Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (February 2015)
Infliximab 10.01.03 Restricted Use NICE TA199:Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis [August 2010]
Infliximab 13.05.03 Non Formulary NICE TA134: Infliximab for psoriasis
Infliximab infusion 01.05.03 Restricted Use NICE TA 329: Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (February 2015)
Infliximab infusion 01.05.03 Restricted Use NICE TA163: Infliximab for acute exacerbations of ulcerative colitis (December 2008)
Infliximab infusion 01.05.03 Restricted Use NICE TA187: Infliximab and adalimumab for the treatment of Crohn’s disease (May 2010)
Irinotecan Hydrochloride 08.01.05 Restricted Use NICE TA440: Pegylated liposomal irinotecan for treating pancreatic cancer after gemcitabine (April 2017)
Irinotecan Hydrochloride 08.01.05 Restricted Use NICE TA307: Aflibercept in combination with irinotecan and fluorouracil-based therapy for treating metastatic colorectal cancer that has progressed following prior oxaliplatin-based chemotherapy (March 2014)
Ivabradine 02.06.03 Non Formulary NICE Guidance on Stable Angina
Ivabradine 02.06.03 Restricted Use NICE TA267: Ivabradine for treating chronic heart failure (Nov 2012)
Ixazomib 08.01.05 Restricted Use NICE TA505: Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma (February 2018)
Ixekizumab 13.05.03 Restricted Use NICE TA537: Ixekizumab for treating active psoriatic arthritis after inadequate response to DMARDs (August 2018)
Ixekizumab 13.05.03 Restricted Use NICE TA442: Ixekizumab for treating moderate to severe plaque psoriasis (April 2017)
Lapatinib 08.01.05 Non Formulary NICE TA257: in combination with an aromatase inhibitor for HER2 positive metastatic breast cancer
Lenalidomide 08.02.04 Restricted Use NICE TA171: Lenalidomide for the treatment of multiple myeloma in people who have received at least one prior therapy (June 2009)
Lenalidomide 08.02.04 Restricted Use NICE TA322: Lenalidomide for treating myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality (September 2014)
Lenalidomide 08.02.04 Restricted Use NICE TA586: Lenalidomide plus dexamethasone for multiple myeloma after 1 treatment with bortezomib (June 2019)
Lenalidomide 08.02.04 Restricted Use NICE TA505: Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma (February 2018)
Lenalidomide 08.02.04 Restricted Use NICE TA587: Lenalidomide plus dexamethasone for previously untreated multiple myeloma (June 2019)
Liraglutide 06.01.02.03 Restricted Use NICE NG28: Type 2 diabetes in adults: management (May 2017)
Lubiprostone 01.02 Restricted Use NICE TA 318 Lubiprostone for treating chronic idiopathic constipation (July 2014)
Memantine 04.11 Restricted Use NICE TA217: Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer’s disease (June 2018)
Metformin 06.01.02.02 Formulary NICE NG28: Type 2 diabetes in adults: management (May 2017)
Methylprednisolone 06.03.02 Formulary NICE CG186: Multiple sclerosis in adults: management (October 2014)
Mirabegron MR Tablets 07.04.02 Restricted Use NICE TA 290 Mirabegron treatment of overactive bladder
Mycophenolate Mofetil 08.02.01 Restricted Use NICE TA85 - Immunosuppressive therapy for renal transplantation in adults (September 2004)
Naloxegol 01.06.06 Restricted Use NICE TA345: Naloxegol for treating opioid-induced constipation (July 2015)
Naltrexone Hydrochloride 04.10.03 Non Formulary NICE TA115: Drug misuse - naltrexone
Naltrexone/bupropion (8mg/90mg) 04.05 Non Formulary NICE TA494: Naltrexone–bupropion for managing overweight and obesity (December 2017)
Natalizumab 08.02.04 Non Formulary NICE TA127: Multiple sclerosis - natalizumab
Nilotinib 08.01.05 Restricted Use NICE TA241: Dasatinib, high-dose imatinib and nilotinib for use in patients who are resistant or intolerant to imatinib (January 2012)
Nilotinib 08.01.05 Restricted Use NICE TA426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia (December 2016)
Nilotinib 08.01.05 Restricted Use NICE TA425: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia (December 2016)
Nintedanib capsules 08.01.05 Restricted Use NICE TA379: Nintedanib for treating idiopathic pulmonary fibrosis (January 2016)
Nintedanib capsules 08.01.05 Restricted Use NICE TA347: Nintedanib for previously treated locally advanced, metastatic, or locally recurrent non‑small‑cell lung cancer (July 2015)
Niraparib 08.01.05 Restricted Use TA528: Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer (July 2018)
Nivolumab 08.01.05 Restricted Use NICE TA462: Nivolumab for treating relapsed or refractory classical Hodgkin lymphoma (July 2017)
Nivolumab 08.01.05 Restricted Use NICE TA483: Nivolumab for previously treated squamous non-small-cell lung cancer (November 2017)
Nivolumab 08.01.05 Restricted Use NICE TA490: Nivolumab for treating squamous cell carcinoma of the head and neck after platinum-based chemotherapy (November 2017)
Nivolumab 08.01.05 Restricted Use NICE TA484: Nivolumab for previously treated non-squamous non-small-cell lung cancer (November 2017)
Nivolumab 08.01.05 Restricted Use NICE TA530: Nivolumab for treating locally advanced unresectable or metastatic urothelial cancer after platinum-containing chemotherapy (June 2018)
Nivolumab 08.01.05 Restricted Use NICE TA558: Nivolumab for adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease (January 2019)
Obeticholic acid 01.09.01 Formulary NICE TA443: Obeticholic acid for treating primary biliary cholangitis (April 2017)
Obinutuzumab 08.02.03 Restricted Use NICE TA513: Obinutuzumab for untreated advanced follicular lymphoma (March 2018)
Obinutuzumab 08.02.03 Restricted Use NICE TA343: Obinutuzumab in combination with chlorambucil for untreated chronic lymphocytic leukaemia (June 2015)
Obinutuzumab 08.02.03 Restricted Use NICE TA472: Obinutuzumab with bendamustine for treating follicular lymphoma refractory to rituximab (August 2017)
Ofatumumab 08.02.03 Restricted Use NICE TA344: Ofatumumab in combination with chlorambucil or bendamustine for untreated chronic lymphocytic leukaemia (June 2015)
Olaparib Capsules 08.01.05 Formulary NICE TA381: Olaparib for maintenance treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy (January 2016)
Omalizumab 03.04.02 Restricted Use NICE TA278: Omalizumab for treating severe persistent allergic asthma (April 2013)
Ombistavir/paritaprevir/ritonavir 05.03.03.02 Restricted Use NICE TA365: Ombitasvir-paritaprevir-ritonavir with or without dasabuvir for treating chronic hepatitis C (November 2015)
Osimertinib mesylate 08.01.05 Restricted Use NICE TA416: Osimertinib for treating locally advanced or metastatic EGFR T790M mutation-positive non-small-cell lung cancer (October 2016)
Oxaliplatin 08.01.05 Restricted Use NICE TA100: Capecitabine and oxaliplatin in the adjuvant treatment of stage III (Dukes’ C) colon cancer (April 2006)
Oxaliplatin 08.01.05 Restricted Use NICE TA212: Bevacizumab in combination with oxaliplatin and either fluorouracil plus folinic acid or capecitabine for the treatment of metastatic colorectal cancer (December 2010)
Paclitaxel 08.01.05 Restricted Use NICE TA476: Paclitaxel as albumin-bound nanoparticles with gemcitabine for untreated metastatic pancreatic cancer (September 2017)
Paclitaxel 08.01.05 Restricted Use NICE TA360: Paclitaxel as albumin-bound nanoparticles in combination with gemcitabine for previously untreated metastatic pancreatic cancer (October 2015)
Paclitaxel 08.01.05 Restricted Use NICE TA55: Guidance on the use of paclitaxel in the treatment of ovarian cancer (January 2003)
Paclitaxel 08.01.05 Restricted Use NICE TA108: Paclitaxel for the adjuvant treatment of early node-positive breast cancer (September 2006)
Palbociclib 08.01.05 Restricted Use NICE TA495: Palbociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer (December 2017)
Panitumumab infusion 08.01.05 Restricted Use NICE TA439: Cetuximab and panitumumab for previously untreated metastatic colorectal cancer (March 2017)
Panobinostat 08.02.04 Formulary NICE TA380: Panobinostat for treating multiple myeloma after at least two previous treatments (January 2016)
Pazopanib 08.01.05 Non Formulary NICE TA215: Renal cell carcinoma (first line metastatic) - pazopanib
Pegaptanib Sodium 11.08.02 Non Formulary NICE guidance on pegaptanib in AMD (August 2008)
Peginterferon Alfa 08.02.04 Non Formulary NICE TA200: Hepatitis C - peginterferon alfa and ribavirin
Peginterferon Alfa 08.02.04 Non Formulary NICE TA106: Hepatitis C - peginterferon alfa and ribavirin
Peginterferon Alfa 08.02.04 Non Formulary NICE TA75: Hepatitis C - pegylated interferons, ribavirin and alfa interferon
Peginterferon Alfa 08.02.04 Restricted Use NICE TA106: Peginterferon alfa and ribavirin for the treatment of mild chronic hepatitis C (August 2006)
Peginterferon Alfa 08.02.04 Restricted Use NICE TA200: Peginterferon alfa and ribavirin for the treatment of chronic hepatitis C (September 2010)
Peginterferon Alfa 08.02.04 Restricted Use NICE TA75: Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of chronic hepatitis C (November 2013)
Pembrolizumab 08.01.05 Restricted Use NICE TA557: Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer (January 2019)
Pembrolizumab 08.01.05 Restricted Use NICE TA428: Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapy (September 2017)
Pembrolizumab 08.01.05 Restricted Use NICE TA540: Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma (September 2018)
Pembrolizumab 08.01.05 Restricted Use NICE TA522: Pembrolizumab for untreated locally advanced or metastatic urothelial cancer when cisplatin is unsuitable (June 2018)
Pembrolizumab 08.01.05 Restricted Use NICE TA519: Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum chemotherapy (April 2018)
Pembrolizumab 08.01.05 Restricted Use NICE TA531: Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer (July 2018)
Pembrolizumab 08.01.05 Restricted Use NICE TA357: Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab (September 2017) [For Specialist or Tertiary Centre use only]
Pembrolizumab 08.01.05 Restricted Use NICE TA366: Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab (September 2017) [For Specialist or Tertiary Centre use only]
Pembrolizumab 08.01.05 Restricted Use NICE TA553: Pembrolizumab for adjuvant treatment of resected melanoma with high risk of recurrence (December 2018) [For Specialist or Tertiary Centre use only]
Pemetrexed 08.01.03 Restricted Use NICE TA402: Pemetrexed maintenance treatment for non-squamous non-small-cell lung cancer after pemetrexed and cisplatin (August 2016)
Pemetrexed 08.01.03 Restricted Use NICE TA181: Pemetrexed for the first-line treatment of non-small-cell lung cancer (September 2009)
Pemetrexed 08.01.03 Restricted Use NICE TA190: Pemetrexed for the maintenance treatment of non-small-cell lung cancer (August 2017)
Pemetrexed 08.01.03 Restricted Use NICE TA135: Pemetrexed for the treatment of malignant pleural mesothelioma (January 2008)
Pertuzumab 08.01.05 Restricted Use NICE TA424: Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer (December 2016)
Pertuzumab 08.01.05 Restricted Use NICE TA569: Pertuzumab for adjuvant treatment of HER2-positive early stage breast cancer (March 2019)
Pertuzumab 08.01.05 Restricted Use NICE TA509: Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer (March 2018)
Pertuzumab 08.01.05 Restricted Use Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer (March 2018)
Pimecrolimus 13.05.03 Non Formulary NICE TA82: Pimecrolimus and tacrolimus for atopic dermatitis (eczema)
Pioglitazone 06.01.02.03 Formulary NICE NG49: Non-alcoholic fatty liver disease (NAFLD): assessment and management (July 2016)
Pipericillin and Tazobactam 05.01.01.04 Restricted Use NICE CG151: Neutropenic sepsis: prevention and management in people with cancer (Sept 2012)
Pixantrone intravenous infusion 08.01.02 Restricted Use NICE TA306: Pixantrone monotherapy for treating multiply relapsed or refractory aggressive non-Hodgkin’s B‑cell lymphoma (February 2014)
Pomalidomide 08.02.04 Restricted Use NICE TA427: Pomalidomide for multiple myeloma previously treated with lenalidomide and bortezomib (January 2017)
Ponatinib 08.01.05 Restricted Use NICE TA451: Ponatinib for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia (June 2017)
Prasugrel 02.09 Restricted Use NICE TA317: Prasugrel with percutaneous coronary intervention for treating acute coronary syndromes (July 2014)
Pregabalin 04.07.03 Restricted Use NICE CG173: Neuropathic pain in adults: pharmacological management in non-specialist settings (April 2018)
Prucalopride 01.06.07 Restricted Use NICE TA 211: Prucalopride for the treatment of chronic constipation in women (December 2010)
Raloxifene Hydrochloride 06.04.01.01 Restricted Use NICE CG164: Familial Breasr Cancer (updated March 2017)
Raloxifene Hydrochloride 06.04.01.01 Restricted Use NICE TA161: Raloxifene and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women (February 2018)
Raloxifene Hydrochloride 06.04.01.01 Restricted Use NICE TA160: Raloxifene for the primary prevention of osteoporotic fragility fractures in postmenopausal women (February 2018)
Ranibizumab 11.08.02 Restricted Use NICE TA237: Ranibizumab for the treatment of diabetic macular oedema (Nov 2011)
Ranibizumab 11.08.02 Restricted Use NICE TA155: Ranibizumab and pegaptanib for the treatment of age-related macular degeneration (May 2012)
Ranolazine 02.06.03 Restricted Use NICE CG126: Stable angina: management (Aug 2016)
Retigabine 04.08.01 Non Formulary NICE guidance, 2011
Ribavirin 05.03.03.02 Restricted Use NICE TA200: Peginterferon alfa and ribavirin for the treatment of chronic hepatitis C (Sept 2010)
Ribavirin 05.03.05 Non Formulary NICE TA106: Hepatitis C - peginterferon alfa and ribavirin
Ribavirin 05.03.05 Non Formulary NICE TA75: Hepatitis C - pegylated interferons, ribavirin and alfa interferon
Ribociclib 08.01.05 Restricted Use NICE TA496: Ribociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer (December 2017)
Riluzole 04.09.03 Restricted Use NICE TA20: Guidance on the use of Riluzole (Rilutek) for the treatment of Motor Neurone Disease (January 2001)
Risedronate 06.06.02 Formulary NICE TA161: Alendronate, etidronate, risedronate, raloxifene, strontium ranelate and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women (February 2018)
Risedronate 06.06.02 Formulary NICE TA160: Alendronate, etidronate, risedronate, raloxifene and strontium ranelate for the primary prevention of osteoporotic fragility fractures in postmenopausal women (February 2018)
Risedronate 06.06.02 Formulary NICE TA464: Bisphosphonates for treating osteoporosis (February 2018)
Rituximab 10.01.03 Restricted Use NICE TA195: Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor [August 2010]
Rituximab 08.02.03 Formulary NICE TA174: Rituximab for the first-line treatment of chronic lymphocytic leukaemia (July 2009)
Rituximab 08.02.03 Formulary NICE TA193: Rituximab for the treatment of relapsed or refractory chronic lymphocytic leukaemia (July 2010)
Rituximab 08.02.03 Formulary TA308: Rituximab in combination with glucocorticoids for treating anti-neutrophil cytoplasmic antibody-associated vasculitis (March 2014)
Rituximab 08.02.03 Formulary NICE TA65 Rituximab for agressive non-Hodgkins lymphoma (September 2003)
Rituximab 08.02.03 Formulary NICE TA243: Rituximab for the first-line treatment of stage III-IV follicular lymphoma (January 2012)
Rituximab 08.02.03 Formulary NICE TA137: Rituximab for the treatment of relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma (February 2008)
Rivaroxaban 02.08.02 Formulary NICE TA335: Rivaroxaban for preventing adverse outcomes after Acute Coronary Syndrome (March 2015)
Rivaroxaban 02.08.02 Formulary NICE TA256: Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation (May 2012)
Rivaroxaban 02.08.02 Formulary NICE TA170: Rivaroxaban for the prevention of venous thromboembolism after total hip or knee replacement surgery in adults (April 09)
Rivaroxaban 02.08.02 Formulary NICE TA287: Rivaroxaban for treating pulmonary embolism and preventing recurrent venous thromboembolism (June 2013)
Rivaroxaban 02.08.02 Formulary NICE TA261: Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism (July 2012)
Rivastigmine 04.11 Restricted Use NICE TA217: Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer’s disease (June 2018)
Roflumilast 03.03.03 Non Formulary NICE Final Appraisal Determination Dec 2011
Roflumilast 03.03.03 Restricted Use NICE TA461: Roflumilast for treating chronic obstructive pulmonary disease (July 2017)
Romiplostim 09.01.04 Restricted Use NICE TA221: Romiplostim for the treatment of chronic immune (idiopathic) thrombocytopenic purpura (Updated May 2014)
Romiplostim 09.01.04 Non Formulary NICE TA221: Thrombocytopenic purpura - romiplostim
Ruxolitinib 08.01.05 Restricted Use NICE TA386: Ruxolitinib for treating disease-related splenomegaly or symptoms in adults with myelofibrosis (March 2016)
Sacubitril and Valsartan 02.05.05.02 Restricted Use NICE TA388: Sacubitril valsartan for treating symptomatic chronic heart failure with reduced ejection fraction (April 2016)
Sarilumab 10.01.03 Restricted Use Sarilumab for moderate to severe rheumatoid arthritis (November 2017)
Secukinumab 13.05.03 Restricted Use NICE TA445: Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs (May 2017)
Secukinumab 13.05.03 Restricted Use NICE TA407: Secukinumab for active ankylosing spondylitis after treatment with NSAIDs or TNF-alpha inhibitors (September 2016)
Secukinumab 13.05.03 Restricted Use NICE TA350: Secukinumab for treating moderate to severe plaque psoriasis (July 2015)
Sofosbuvir 05.03.03.02 Restricted Use NICE TA330 Sofosbuvir for treating chronic hepatitis C (Feb 2015)
Sofosbuvir/ledipasvir 05.03.03.02 Restricted Use NICE TA363: Ledipasvir-sofosbuvir for treating chronic hepatitis C (November 2015)
Sofosbuvir/velpatasvir 05.03.03.02 Restricted Use NICE TA430: Sofosbuvir-velpatasvir for treating chronic hepatitis C (January 2017)
Sofosbuvir-velpatasvir-voxilaprevir 05.03.03.02 Restricted Use NICE TA507: Sofosbuvir–velpatasvir–voxilaprevir for treating chronic hepatitis C
Somatropin 06.05.01 Restricted Use NICE TA64: Human growth hormone (somatropin) in adults with growth hormone deficiency (2003)
Somatropin 06.05.01 Restricted Use NICE TA188: Human growth hormone (somatropin) for the treatment of growth failure in children (2010)
Sorafenib 08.01.05 Non Formulary NICE TA189: Hepatocellular carcinoma (advanced and metastatic) - sorafenib (first line)
Sunitinib 08.01.05 Non Formulary NICE TA179: Gastrointestinal stromal tumours - sunitinib
Sunitinib 08.01.05 Non Formulary NICE TA178: Renal cell carcinoma
Sunitinib 08.01.05 Non Formulary NICE TA169: Renal cell carcinoma - sunitinib
Tacrolimus 13.05.03 Non Formulary NICE TA82: Pimecrolimus and tacrolimus for atopic dermatitis (eczema)
Tamoxifen 08.03.04.01 Formulary NICE CG164: Familial Breast Cancer (updated March 2017)
Tegafur with Uracil 08.01.03 Non Formulary NICE TA61: Capcitabine and tegafur - Colorectal cancer
Telaprevir 05.03.03.02 Restricted Use NICE TA252: Telaprevir for the treatment of genotype 1 chronic hepatitis C (April 2012)
Temozolomide 08.01.05 Non Formulary NICE TA23: Brain cancer - temozolomide
Temozolomide 08.01.05 Non Formulary NICE TA121: Glioma (newly diagnosed and high grade) - carmustine implants and temozolomide
Temsirolimus 08.01.05 Non Formulary NICE TA207: Mantle cell lymphoma (relapsed) - temsirolimus (terminated appraisal)
Temsirolimus 08.01.05 Non Formulary NICE TA178: temsirolimus for first-line treatment of advanced and/or metastatic renal cell carcinoma
Tenofovir Disproxil 05.03.03.01 Restricted Use NICE TA173: Tenofovir disoproxil for the treatment of chronic hepatitis B (July 2009)
Teriparatide 06.06.01 Formulary NICE TA161: Raloxifene and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women (February 2018)
Thalidomide 08.02.04 Restricted Use NICE TA228: Bortezomib and thalidomide for the first‑line treatment of multiple myeloma (July 2011)
Ticagrelor 02.09 Restricted Use NICE TA420: Ticagrelor for preventing atherothrombotic events after myocardial infarction (December 2016)
Ticagrelor 02.09 Restricted Use NICE TA236 - Ticagrelor for the Treatment of Acute Coronary Syndromes (October 2011)
Tiotropium 03.01.02 Formulary NICE ESNM55: Asthma - tiotropium (March 2015)
Tocilizumab 10.01.03 Restricted Use NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed (January 2016)
Tocilizumab 10.01.03 Restricted Use NICE TA518: Tocilizumab for treating giant cell arteritis (April 2018)
Tocilizumab 10.01.03 Restricted Use NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis (December 2015)
Tocilizumab 10.01.03 Restricted Use NICE TA247: Tocilizumab for the treatment of rheumatoid arthritis [February 2012]
Tofacitinib 10.01.03 Restricted Use NICE TA480: Tofacitinib for moderate to severe rheumatoid arthritis (October 2017)
Tofacitinib 10.01.03 Restricted Use NICE TA543: Tofacitinib for treating active psoriatic arthritis after inadequate response to DMARDs (October 2018)
Tofacitinib 01.05.03 Restricted Use NICE TA547: Tofacitinib for moderately to severely active ulcerative colitis (November 2018)
Topiramate 04.08.01 Restricted Use NICE CG150: Headaches in over 12s: diagnosis and management (Nov 2015)
Topotecan 08.01.05 Restricted Use NICE TA183: Topotecan for the treatment of recurrent and stage IVB cervical cancer (October 2009)
Topotecan 08.01.05 Restricted Use NICE TA389: Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer (April 2016)
Topotecan 08.01.05 Restricted Use NICE TA184: Topotecan for the treatment of relapsed small-cell lung cancer (November 2009)
Topotecan 08.01.05 Restricted Use NICE TA91: Paclitaxel, pegylated liposomal doxorubicin hydrochloride and topotecan for second-line or subsequent treatment of advanced ovarian cancer (May 2005)
Trabectedin 08.01.05 Non Formulary NICE TA222- ovarian cancer
Trabectedin 08.01.05 Non Formulary NICE TA185: Soft tissue sarcoma - trabectedin
Trastuzumab 08.01.05 Restricted Use NICE TA208: Trastuzumab for the treatment of HER2-positive metastatic gastric cancer (November 2010)
Trastuzumab 08.01.05 Restricted Use NICE TA34: Guidance on the use of trastuzumab for the treatment of advanced breast cancer (March 2002)
Trastuzumab 08.01.05 Restricted Use NICE TA257: Lapatinib or trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone-receptor-positive breast cancer that overexpresses HER2 (June 2012)
Trastuzumab emtansine 08.01.05 Restricted Use NICE TA509: Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer (March 2018)
Trastuzumab emtansine 08.01.05 Restricted Use NICE TA458: Trastuzumab emtansine for treating HER2-positive advanced breast cancer after trastuzumab and a taxane (July 2017)
Trifluridine-tipiricil 08.01.03 Restricted Use NICE TA405: Trifluridine–tipiracil for previously treated metastatic colorectal cancer (August 2016)
Ustekinumab 10.01.03 Restricted Use NICE TA340: Ustekinumab for treating active psoriatic arthritis [June 2015]
Ustekinumab 10.01.03 Restricted Use NICE TA180: Ustekinumab for the treatment of adults with moderate to severe psoriasis (updated March 2017)
Ustekinumab 10.01.03 Restricted Use NICE TA455: Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people (July 2017)
Ustekinumab injection 01.05.03 Restricted Use NICE TA456: Ustekinumab for moderately to severely active Crohn’s disease after previous treatment
Varenicline 04.10.02 Restricted Use NICE TA123: Varenicline for smoking cessation (July 2007)
Vedolizumab 01.05.03 Restricted Use NICE TA342: Vedolizumab for treating moderately to severely active ulcerative colitis (June 2015)
Vedolizumab 01.05.03 Restricted Use NICE TA352: Vedolizumab for treating moderately to severely active Crohn’s disease after prior therapy (August 2015)
Venetoclax 08.01.05 Restricted Use NICE TA487: Venetoclax for treating chronic lymphocytic leukaemia (November 2017)
Venetoclax 08.01.05 Restricted Use NICE TA561: Venetoclax with rituximab for previously treated chronic lymphocytic leukaemia (February 2019)
Venlafaxine 04.03.04 Formulary NICE CG90: Depression in adults: Recognition and Management (Updated April 2016)
Vitamin B Compound Strong 09.06.02 Formulary Alcohol-use disorders: diagnosis, assessment and management of harmful drinking and alcohol dependence (February 2011)
Vortioxetine 04.03.04 Restricted Use NICE TA367: Vortioxetine for treating major depressive episodes (November 2015)
Zoledronic Acid (5mg/100ml) 06.06.02 Restricted Use NICE TA464: Bisphosphonates for treating osteoporosis (February 2018))
Zolpidem 04.01.01 Formulary NICE TA77: Guidance on the use of zaleplon, zolpidem and zopiclone for the short-term management of insomnia (April 2004)
Zopiclone 04.01.01 Formulary NICE TA77: Guidance on the use of zaleplon, zolpidem and zopiclone for the short-term management of insomnia (April 2004)
Joint Medicines Formulary